Cervical human papillomavirus prevalence and genotype distribution among hybrid capture 2 positive women 15 to 64 years of age in the Gurage zone, rural Ethiopia

Infectious Agents and Cancer

Volumn 9, Issue 1, 2014, Pages

  Leyh Bannurah, Sami Ramzi ^a   Prugger, Christof ^b,c   De Koning, Maurits N C ^d   Goette, Hartmut ^e   Lellé, Ralph J ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c INSERM   (France)

^d DDL DIAGNOSTIC LABORATORY   (Netherlands)

^e QIAGEN GMBH   (Germany)

Author keywords

Cervix uteri; DNA probes; Epidemiology; Ethiopia; HPV; Papillomavirus infections; Risk factors; Sub Sahara Africa

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; ETHIOPIA; FEMALE; GENOTYPE; HIGH RISK PATIENT; HOUSING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; LIFESPAN; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PREVALENCE; SEXUALITY; WART VIRUS; WIDOW;

EID: 84908006259     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-9-33     Document Type: Article

References (37)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F, GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet] International Agency for Research on Cancer: Lyon, France 2013 Available from: http://globocan.iarc.fr, accessed on 01/12/2013
2. WHO/ICO Information Centre on HPV and Cervical Cancer, (HPV Information Centre), Human Papillomavirus and Related Cancers in Ethiopia. Summary Report 2010 Available from: http://www.hpvcentre.net, accessed on 01/06/2011
3. Chapter 1: HPV in the etiology of human cancer. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L, Vaccine 2006 24 Suppl 3 3/1 10
4. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa. Kim JJ, Campos NG, O'Shea M, Diaz M, Mutyaba I, Vaccine 2013 31 Suppl 5 60 F72 24331749
5. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT, Bosch FX, Ferreccio C, Hieu NT, Lazcano-Ponce E, Matos E, Molano M, Qiao YL, Rajkumar R, Ronco G, de Sanjose S, Shin HR, Sukvirach S, Thomas JO, Meijer CJ, Munoz N, Int J Cancer 2006 119 2677 2684 10.1002/ijc.22241 16991121
6. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM, Int J Cancer 2011 128 927 935 10.1002/ijc.25396 20473886
7. Post-licensure monitoring of HPV vaccine in the United States. Markowitz LE, Hariri S, Unger ER, Saraiya M, Datta SD, Dunne EF, Vaccine 2010 28 4731 4737 10.1016/j.vaccine.2010.02.019 20188681
8. Monitoring the coverage and impact of human papillomavirus vaccine-report of WHO meeting, November 2009. World Health Organization, Wkly Epidemiol Rec 2010 85 237 243 20583384
9. Pospieschil A, Das Attat Hospital in Äthiopien. Charity-Page [Internet] Available from: http://www.attat-hospital.de/, accessed on 01/01/2013
10. Prevalence of human papilloma virus infection in women in rural Ethiopia. Ruland R, Prugger C, Schiffer R, Regidor M, Lelle RJ, Eur J Epidemiol 2006 21 727 729 10.1007/s10654-006-9055-4 17072541
11. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA, Science 1988 239 487 491 10.1126/science.2448875 2448875
12. High genotyping concordance between the digene HPV genotyping RH test and the reverse line blot genotyping assay on GP5+/6 + -PCR products. Geraets DT, Heideman DA, de Koning MN, Snijders PJ, Meijer CJ, van Doorn LJ, Quint WG, J Clin Virol 2009 46 Suppl 3 16 S20
13. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. Kleter B, van Doorn LJ, Schrauwen L, Molijn A, Sastrowijoto S, ter Schegget J, Lindeman J, ter Harmsel B, Burger M, Quint W, J Clin Microbiol 1999 37 2508 2517 10405393
14. Doll R, Payne P, Waterhouse J, Cancer incidence in five continents: a technical report. International Union Against Cancer (IUAC) Berlin: Springer-Verlag 1966
15. The carcinogenicity of human papillomavirus types reflects viral evolution. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, Wright TC, Solomon D, Chen Z, Schussler J, Castle PE, Burk RD, Virology 2005 337 76 84 10.1016/j.virol.2005.04.002 15914222
16. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. Schellenbacher C, Roden R, Kirnbauer R, J Virol 2009 83 10085 10095 10.1128/JVI.01088-09 19640991
17. Age-specific prevalence of infection with human papillomavirus in females: a global review. Smith JS, Melendy A, Rana RK, Pimenta JM, J Adolesc Health 2008 43 5 S25 S25 e21-41 18809145
18. The age-specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: implications for screen-and-treat strategies. Gage JC, Ajenifuja KO, Wentzensen NA, Adepiti AC, Eklund C, Reilly M, Hutchinson M, Wacholder S, Harford J, Soliman AS, Burk RD, Schiffman M, Int J Cancer 2012 130 2111 2117 10.1002/ijc.26211 21630264
19. Prevalence and risk factors for carcinogenic human papillomavirus infections in rural Rakai, Uganda. Safaeian M, Kiduggavu M, Gravitt PE, Gange SJ, Ssekasanvu J, Muroka D, Sklar M, Serwada D, Wawer MJ, Shah KV, Gray R, Sex Transm Infect 2008 84 306 311 10.1136/sti.2007.027318 18385223
20. Human papillomavirus genotypes in rural Mozambique. Castellsague X, Menendez C, Loscertales MP, Kornegay JR, dos Santos F, Gomez-Olive FX, Lloveras B, Abarca N, Vaz N, Barreto A, Bosch FX, Alonso P, Lancet 2001 358 1429 1430 10.1016/S0140-6736(01)06523-0 11705494
21. HPV infection in Europe. De Vuyst H, Clifford G, Li N, Franceschi S, Eur J Cancer 2009 45 2632 2639 10.1016/j.ejca.2009.07.019 19709878
22. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX, Lancet Infect Dis 2007 7 453 459 10.1016/S1473-3099(07)70158-5 17597569
23. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, Sherman ME, Wacholder S, Tarone R, Burk RD, J Infect Dis 2005 191 1808 1816 10.1086/428779 15871112
24. A population-based cross-sectional study of age-specific risk factors for high risk human papillomavirus prevalence in rural Nigeria. Clarke MA, Gage JC, Ajenifuja KO, Wentzensen NA, Adepiti AC, Wacholder S, Burk RD, Schiffman M, Infect Agent Cancer 2011 6 12 10.1186/1750-9378-6-12 21801395
25. Cross-neutralizing antibodies elicited by the Cervarix(R) human papillomavirus vaccine display a range of Alpha-9 inter-type specificities. Bissett SL, Draper E, Myers RE, Godi A, Beddows S, Vaccine 2014 32 1139 1146 10.1016/j.vaccine.2014.01.008 24440205
26. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes. Barzon L, Squarzon L, Masiero S, Pacenti M, Marcati G, Mantelli B, Gabrielli L, Lazzarotto T, Caputo A, Palu G, Vaccine 2014 32 5357 5362 10.1016/j.vaccine.2014.07.014 25045814
27. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Guan P, Howell-Jones R, Li N, Bruni L, de Sanjose S, Franceschi S, Clifford GM, Int J Cancer 2012 131 2349 2359 10.1002/ijc.27485 22323075
28. Prevalence, incidence and risk factors for anogenital warts in Sub Saharan Africa: a systematic review and meta analysis. Banura C, Mirembe FM, Orem J, Mbonye AK, Kasasa S, Mbidde EK, Infect Agent Cancer 2013 8 27 10.1186/1750-9378-8-27 23842471
29. The prevalence of cervical cytology abnormalities and human papillomavirus in women infected with the human immunodeficiency virus. Dames DN, Ragin C, Griffith-Bowe A, Gomez P, Butler R, Infect Agent Cancer 2009 4 1 8 10.1186/1750-9378-4-8 19208213
30. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Lazcano-Ponce E, Herrero R, Munoz N, Cruz A, Shah KV, Alonso P, Hernandez P, Salmeron J, Hernandez M, Int J Cancer 2001 91 412 420 10.1002/1097-0215(20010201)91:3<412::AID-IJC1071>3.0.CO;2-M 11169968
31. Central Statistical Agency [Ethiopia], Ethiopia Demographic and Health Survey 2005 Ethiopia and Calverton, Maryland, USA: Central Statistical Agency and ORC Macro Addis Ababa 2006
32. Reproductive factors, oral contraceptive use, and human papillomavirus infection: pooled analysis of the IARC HPV prevalence surveys. Vaccarella S, Herrero R, Dai M, Snijders PJ, Meijer CJ, Thomas JO, Hoang Anh PT, Ferreccio C, Matos E, Posso H, de Sanjose S, Shin HR, Sukvirach S, Lazcano-Ponce E, Ronco G, Rajkumar R, Qiao YL, Munoz N, Franceschi S, Cancer Epidemiol Biomarkers Prev 2006 15 2148 2153 10.1158/1055-9965.EPI-06-0556 17119039
33. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch FX, Cuzick J, Dillner J, Heideman DA, Snijders PJ, Int J Cancer 2009 124 516 520 10.1002/ijc.24010 18973271
34. Comparison of the SPF10-LiPA system to the hybrid capture 2 assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in Guanacaste, Costa Rica. Safaeian M, Herrero R, Hildesheim A, Quint W, Freer E, Van Doorn LJ, Porras C, Silva S, Gonzalez P, Bratti MC, Rodriguez AC, Castle P, J Clin Microbiol 2007 45 1447 1454 10.1128/JCM.02580-06 17344361
35. Human papillomavirus genotype specificity of hybrid capture 2. Castle PE, Solomon D, Wheeler CM, Gravitt PE, Wacholder S, Schiffman M, J Clin Microbiol 2008 46 2595 2604 10.1128/JCM.00824-08 18579716
36. Efficiency of the hybrid capture 2 HPV DNA test in cervical cancer screening. A study by the French society of clinical cytology. de Cremoux P, Coste J, Sastre-Garau X, Thioux M, Bouillac C, Labbe S, Cartier I, Ziol M, Dosda A, Le Gales C, Molinie V, Vacher-Lavenu MC, Cochand-Priollet B, Vielh P, Magdelenat H, Am J Clin Pathol 2003 120 492 499 10.1309/XFUCPP6M5XUA94B8 14560561
37. Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program. Hesselink AT, Bulkmans NW, Berkhof J, Lorincz AT, Meijer CJ, Snijders PJ, J Clin Microbiol 2006 44 3680 3685 10.1128/JCM.02078-05 17021097